Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Medical System Holdings Limited (0867.HK)
North Point, HK
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.32% | -3.38% | -17.28% | -27.53% | -20.45% | -17.98% | -1.31% | -5.37% | -46.83% | -5.54% | +251.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.0% ★ Q4'25: +23.7% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-7.5% Q4'25: +10.0% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.0% Q4'25: -7.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.2% ★ Q4'25: +17.7% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.7% ★ Q4'25: +14.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q4'25: -1.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.38× ★ Q4'25: 0.19× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 2 EPS Ana. |
Dec 2027 8 Rev. Ana. 2 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.55B
est: 4.37B (-18.6%)
|
4.90B
est: 5.45B (-10.1%)
|
5.35B
est: 6.95B (-23.0%)
|
5.43B
est: 6.33B (-14.2%)
|
6.07B
est: 6.68B (-9.1%)
|
6.95B
est: 7.89B (-11.9%)
|
8.34B
est: 10.08B (-17.3%)
|
9.15B
est: 10.81B (-15.4%)
|
8.01B
est: 9.75B (-17.8%)
|
7.47B
est: 7.69B (-2.9%)
|
8.21B
est: 8.18B (+0.3%)
|
10.30B
10.13B – 10.45B
+25.8% YoY
|
12.46B
10.74B – 13.13B
+21.0% YoY
|
15.14B
13.90B – 15.68B
+21.5% YoY
|
| EBITDA |
1.17B
est: 1.72B (-32.2%)
|
1.69B
est: 2.15B (-21.2%)
|
2.09B
est: 2.74B (-23.7%)
|
2.20B
est: 2.49B (-11.7%)
|
2.75B
est: 2.63B (+4.5%)
|
3.05B
est: 3.11B (-1.7%)
|
3.70B
est: 3.97B (-6.7%)
|
3.76B
est: 4.26B (-11.6%)
|
2.92B
est: 3.84B (-23.9%)
|
2.31B
est: 2.69B (-14.3%)
|
1.82B
est: 2.87B (-36.3%)
|
3.61B
3.55B – 3.66B
+25.8% YoY
|
4.36B
3.76B – 4.60B
+21.0% YoY
|
5.30B
4.87B – 5.49B
+21.5% YoY
|
| EBIT |
1.09B
est: 1.60B (-31.9%)
|
1.54B
est: 1.99B (-22.6%)
|
1.89B
est: 2.54B (-25.6%)
|
2.08B
est: 2.31B (-10.2%)
|
2.54B
est: 2.44B (+4.1%)
|
2.84B
est: 2.88B (-1.4%)
|
3.48B
est: 3.69B (-5.5%)
|
3.55B
est: 3.95B (-10.1%)
|
2.71B
est: 3.57B (-23.9%)
|
2.05B
est: 2.48B (-17.3%)
|
1.58B
est: 2.64B (-40.1%)
|
3.32B
3.27B – 3.37B
+25.8% YoY
|
4.01B
3.46B – 4.23B
+21.0% YoY
|
4.88B
4.48B – 5.05B
+21.5% YoY
|
| Net Income |
995.94M
est: 1.23B (-19.2%)
|
1.38B
est: 1.45B (-4.9%)
|
1.67B
est: 1.96B (-14.3%)
|
1.85B
est: 2.16B (-14.4%)
|
1.96B
est: 2.40B (-18.2%)
|
2.53B
est: 2.86B (-11.4%)
|
3.02B
est: 3.56B (-15.2%)
|
3.26B
est: 4.05B (-19.5%)
|
2.40B
est: 3.47B (-30.7%)
|
1.62B
est: 1.89B (-14.1%)
|
1.49B
est: 1.65B (-10.0%)
|
2.08B
2.00B – 2.17B
+25.9% YoY
|
2.47B
2.38B – 2.57B
+18.7% YoY
|
2.98B
2.66B – 3.12B
+20.5% YoY
|
| SGA |
1.01B
est: 1.67B (-39.7%)
|
1.40B
est: 2.09B (-33.1%)
|
1.60B
est: 2.66B (-39.6%)
|
1.92B
est: 2.42B (-20.9%)
|
2.19B
est: 2.56B (-14.3%)
|
2.30B
est: 3.02B (-23.6%)
|
2.98B
est: 3.86B (-22.7%)
|
3.36B
est: 4.14B (-18.8%)
|
3.17B
est: 3.73B (-15.1%)
|
3.44B
est: 3.13B (+10.1%)
|
3.71B
est: 3.33B (+11.5%)
|
4.19B
4.12B – 4.25B
+25.8% YoY
|
5.06B
4.37B – 5.34B
+21.0% YoY
|
6.15B
5.65B – 6.37B
+21.5% YoY
|
| EPS |
0.40
est: 0.51 (-21.2%)
|
0.55
est: 0.60 (-7.7%)
|
0.67
est: 0.81 (-16.8%)
|
0.74
est: 0.89 (-16.9%)
|
0.79
est: 0.99 (-20.0%)
|
1.02
est: 1.18 (-13.3%)
|
1.22
est: 1.47 (-16.7%)
|
1.33
est: 1.67 (-20.2%)
|
0.98
est: 1.43 (-31.4%)
|
0.67
est: 0.78 (-14.1%)
|
0.62
est: 0.68 (-9.3%)
|
0.86
0.82 – 0.90
+25.9% YoY
|
1.02
0.98 – 1.06
+18.7% YoY
|
1.23
1.10 – 1.29
+20.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-14 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kong Lam | Founder, Chairman, Chief Executive Officer & President | 7M | male |
| Yanling Chen | Chief Financial Officer, Vice President & Executive Director | 5M | female |
| James Patrick Stearns | Chief Investment Officer of Europe & America | — | male |
| Fei Jiang | Chief Investment Officer of Greater China | — | male |
| Liu Yue | Director of Investor Relations | — | — |
| Sanyan Wu | Director of Legal Department & Company Secretary | — | female |
| Lieyi Ma | General Manager of the Operations & Management Center of the Group | — | male |
| Huaizheng Peng | Chief Business Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0867.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
